Figure 3. LXR agonism increases tumor-infiltrating activated CD8⁺ and CD4⁺ T cells.

(A) Suppressive properties of splenic MDSCs isolated from tumor bearing mice treated in vivo with control or RGX-104 (100 mg/kg) chow for 48 hours—as assessed by CD8⁺ T cell activation (IFN-γ expression) and proliferation (BV dilution) after co-culture in vitro. Representative contour plots show IFN-γ expression and BV fluorescence of CD8⁺ cells (n = 4).

(B) Percent IFN-γ and Granzyme B (GZM-B) expressing, activated CD8⁺ T cells of total CD45⁺ TILs from B16F10 tumors of control or GW3965-treated mice (100 mg/kg) after 10 days of treatment (n = 6). Representative contour plots show percentages of double positive cells.

(C) Percent PD-1⁺ CD8⁺ T cells of total tumor-infiltrating CD8⁺ T cells from B16F10 tumors of control or GW3965-treated mice (100 mg/kg; 10 days) (n = 6).

(D) Correlation between tumor-infiltrating CD8⁺IFN-γ⁺GZM-B⁺ T cells and G-MDSCs, reported as percentages of total CD8⁺ and CD45⁺ TILs, respectively (n = 20).

(E) Percent CD4⁺IFN-γ⁺TNFα⁺ T cells of total CD45⁺ TILs from B16F10 tumors treated for 10 days with control or GW3965 (100 mg/kg) (n = 6).

Data represent mean ± s.e.m. See also Figure S3.